Current HCV Treatment:
FDA
approved medications to treat hepatitis C, side effect management, disease
progression after successful treatment, and treatment of various populations of
people with hepatitis C.
·
Disease Progression
o 361. Eradication of HCV
Improves Hepatic Expression of Insulin Receptor Substrate 1/2 and Insulin
Resistance.
o
M1882. Does antiviral therapy
affect liver cirrhosis progression?
o S1240. Sustained virologic
response to previous interferon treatment may reduce the risk for the
recurrence of hepatocellular carcinoma in patients with hepatitis C (updated, May 20)
o S1728 The Prevalence and Significance of Occult Hepatitis B In A Liver
Transplant population with Chronic Hepatitis C
·
General
o 362. Restoration Of Innate
Immunity And Inhibition of Essential Host Factor For Replication Achieve Better
Clinical Effect In Patients With Chronic Hepatitis C
o M1005. Prevalence and clinical
significance of hepatitis G virus coinfection in patients with chronic
hepatitis C undergoing antiviral therapy. (updated, May 28)
o M1802. Post-treatment
intrahepatic gene expression profiles associated with long-term virologic
responses following peginterferon and ribavirin treatment for HCV genotype 1.
o M1845. Retrospective Analysis of
the Effect of Taking a Statin Along with Peginterferon and Ribavirin (PI+R) on
SVR. (updated, May 22)
o M1852. Role Of
Hmg-Coa Reductase Therapy In Hepatitis C (HCV) Treatment Outcomes. (updated, May 21)
o M1858. Cardiac stress test may
not be indicated in patients with cardiac risk factors prior to antiviral
therapy for chronic HCV. (updated, May 22)
o M1859. Does RVR Predict SVR in Patients
with Chronic HCV Genotype 2/3 Treated with Peginterferon and Ribavirin?
o M1860. Peripheral Blood Leukocyte Ifnar-2 Expression in Aging
Patients with Chronic Hepatitis C and an Effect of Ifn Therapy (updated, May 22)
o M1864. Predictors of Treatment Among
Patients With Chronic Hepatitis C Virus Infection.
o M1866. Antiviral Completion
Rates and Sustained Viral Response in Hepatitis C Patients with- versus
without- Pre-existing Major Depressive Disorder.
o M1870. Satisfaction with the
decision to defer treatment for chronic hepatitis C (CHCV) infection declines
over time: results of a 2-year follow-up questionnaire survey.
o M1872. Safety and Tolerability
of Peginterferon α-2a/Ribavirin in HCV Patients Non-Tolerant or
Nonresponsive to Peginterferon α-2b/Ribavirin. (updated,
May 22)
o M1880. Determining Current Barriers to Clinical Assessment and
Antiviral Treatment in a cohort of U.S. Veterans referred for HCV Evaluation.
(updated,
May 22)
o S1232. Efficacy of a 72-week course of treatment for previous relapsers to
PEG/ribavirin therapy (updated, May 20)
o W1150. Antiviral treatment in Crohn ’s patients with chronic hepatitis C is well tolerated
and effective.
·
Pegasys
o 4. Increased SVR Rate with 48
Wks’ Treatment and Higher RBV Dose in HCV Genotype 2/3 Pts Without a Rapid
Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS®)
Plus RBV (COPEGUS®) (updated, May 28)
o 441. Peginterferon Alfa-2a
(40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection
and Advanced Fibrosis/Cirrhosis (updated, May 28)
o 444. Sustained Virologic Response
(SVR) Resulting From Treatment with Peginterferon Alfa-2a (40KD) (PEGASYS®)
Alone or in Combination with Ribavirin (COPEGUS®) is Durable and Constitutes a
Cure: an Ongoing 5-year Follow-up. (updated,
May 21)
o M1846. Cost-effectiveness of Early Treatment of Chronic Hepatitis C
With Peginterferon Alfa-2a (40KD) Plus Ribavirin
Before Progression to Advanced Liver Disease. (updated May 23)
o M1849. Herbal and Milk Thistle
Use in the HALT-C Trial of Advanced Chronic Hepatitis C. (updated
May 23)
o M1854. Treatment Duration and Histological Response to
Peginterferon Alfa-2a/Ribavirin. (updated May 24)
o M1856. Treatment of chronic hepatitis C (CHC) with peginterferon
alfa-2a (40kd) (PEG) and ribavirin (RBV) in patients older than 60 years (updated May 24)
o M1861. Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in
Methadone Maintenance Patients: Randomized Comparison of Direct Observed
Therapy and Self Administration (updated
May 23)
o W1013. Predictive factors of
sustained virological response to peginterferon alpha-2a therapy in the
patients with chronic hepatitis C despite the discontinuation of peginterferon
alpha-2a therapy due to adverse events.
·
Peg-Intron
o
M1881. Effect
of Peginterferon α-2b and Ribavirin combined therapy on serum gastrin and progastrin
levels in relation to Helicobacter pylori (Hp) infection in patients with
chronic hepatitis C (CHC).
·
Side effects
o M1863. Prevalence and Risk
Factors of Thyroid Disease in Patients Treated For Hepatitis C Virus. (updated
May 23)
o M1871. Darbepoetin Alfa and
Filgrastim for the Management of Anemia and Neutropenia in Chronic Hepatitis C
(CH-C).
o T1044. Eltrombopag Maintains
Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of
Chronic Hepatitis C Virus Infection. (updated May 23)
o Psychosocial
§
M1813. Genome-wide analysis for genes
that mediate IFN-induced depression in HCV patients.